Botanix Pharmaceuticals (BXPHF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the webinar. I'm Vince Ippolito, the Executive Chairman of the Board for Botanics Pharmaceuticals Limited. Here it is the top of the hour. We're expecting close to 300 participants with pre-registrations and those that are continuing to come on right now as we speak. But we're going to get started with today's webinar. Well, the company's come a long way since our highly successful commercial launch of Softra. in February of 2025. It's really hard to believe that was just a little bit more than a year ago we launched. And we're pleased with the progress the company's made and with the approval of the balance of the capital raise later this month, we believe that we'll be well positioned for future growth. Well, the purpose of this call today is to discuss the 2026 half-year report. And at the end of the presentation, we'll have some time for some questions from the audience regarding the report. You could type them into the chat section there. We'll try to capture as many as we can. We've got a few questions in advance as well of this webinar that we're going to incorporate into the Q&A as well. And for all participants, all questions are monitored and moderated. And I'm joined here, as you can see on the screen today, by our Chief Executive Officer, Dr. Howie McGibbon, and the U.S. Chief Financial Officer, Chris Lesovitz, who will take you through today's presentation of the Botanics Half-Year Report for the period ending 31 December 2025. So with that, I'm going to turn the presentation over to Howie to get us started here. All right. Thank you, Vince, and thank you to all the attendees for taking the time to join the call today. So today I'm going to provide a summary, a brief company overview, and then we're going to quickly move over ...